title: Comment on Campana et al.: radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence.
authors.affiliation: Department of Nuclear Medicine, University Hospital Bonn, Sigmund-Freud-Str. 25, 53105, Bonn, Germany, samer.ezziddin@ukb.uni-bonn.de.
authors.forename: Samer
authors.initials: S
authors.lastname: Ezziddin
authors.forename: Amir
authors.initials: A
authors.lastname: Sabet
authors.forename: Charlotte Jane
authors.initials: CJ
authors.lastname: Yong-Hing
authors.forename: Hans-Jürgen
authors.initials: HJ
authors.lastname: Biersack
mesh_terms: D005260:Female; D006801:Humans; D007414:Intestinal Neoplasms / Q000532:radiotherapy*; D008297:Male; D018358:Neuroendocrine Tumors / Q000532:radiotherapy*; D015282:Octreotide / Q000031:analogs & derivatives*; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000532:radiotherapy*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D013004:Somatostatin / Q000031:analogs & derivatives*; D013274:Stomach Neoplasms / Q000532:radiotherapy*
chemical_list: D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; D013004:Somatostatin; D015282:Octreotide